iCure BNP

iCure BNP is a South Korean biotech subsidiary of iCure focused on drug delivery technologies that convert injectable or poorly absorbed medicines into non-invasive formulations, especially oral products. The company appears to specialize in permeability-enhancing and absorption technologies for peptides and oncology drugs, with disclosed work on oral liraglutide, oral oxaliplatin, oral pemetrexed, and teriparatide-related formulations. Public disclosures also indicate activity in adjacent delivery areas such as intranasal biobetters, microneedles, and lipid nanoparticle drug technologies. Compared with parent company iCure's transdermal patch business, iCure BNP seems to represent a platform-oriented R&D vehicle for next-generation bioavailability enhancement and reformulation programs.